Forscherin im Labor

Welcome to Merz

Merz is an independent international pharmaceutical company with its own research and development. Core competences are medical and aesthetic dermatology and neurological movement disorders.

In the aesthetics field, Merz offers a well-balanced range of products for minimally invasive wrinkle treatments and volume augmentation. With its brands for hair loss and scar treatment, Merz is an important player in medical dermatology.
Read more


  • 06. February 2015

    Merz and SHOFU Enter Agreement Regarding Sale of Merz Dental

    Frankfurt am Main/Kyoto, January 6, 2015. Merz Pharma has entered an agreement to sell Merz Dental to the Japanese dental materials and equipment manufacturer SHOFU. This divestiture will enable Merz Pharma to focus on its core business, while giving SHOFU the opportunity to strengthen its position as a leading dental manufacturer.

  • 07. November 2014

    Validation of Alternative Test Method for Botulinum Neurotoxin

    Frankfurt am Main, November 7, 2014 – Merz, the pharmaceuticals company, has successfully completed validation of an in vitro assay for testing the potency and stability of its botulinum neurotoxin. The cell culture-based assay has been submitted to the Bundesinstitut für Arzneimittel und Medizinprodukte in Germany and the FDA, the U.S. regulatory authority.

  • 07. October 2014

    Merz’s New Strategy Sets the Stage for Successful Growth

    Frankfurt am Main, October 7, 2014 – As forecast, the Merz Pharma Group cushioned the impact of lower royalties in fiscal year 2013/14 through organic growth in its core businesses, Aesthetics and Neurotoxins. At EUR 994 million, Group revenue was on par with the prior-year figure, showing a moderate 1.4% increase. EBIT was EUR 247.2 million, a decrease of EUR 88.7 million compared with the prior-year figure due to a falloff in royalties on Memantine, a drug for treating dementia, and to higher spending on research and development and on lifecycle management for existing products. Accordingly, the EBIT margin—earnings before interest and tax as a percentage of revenue—decreased from 34.3% to 24.9%.

  • 30. July 2014

    COMPANY ULTHERA, INC. Company`s Largest Acquisition Strengthens Aesthetics Business

    Frankfurt, Greensboro, N.C. and Mesa, A.Z. – July 29, 2014 – Merz and Ulthera, Inc. have finalized a transaction for Merz to acquire the global medical device company, officials announced today. This announcement follows gaining necessary regulatory approvals from the U.S. Trade Commission and the U.S. Department of Justice.

  • 26. June 2014

    MERZ TO ACQUIRE ULTHERA, INC., a leading energy device company in the area of non-invasive lift

    Merz and Ulthera, Inc. today announced that they have entered a definitive merger agreement, pursuant to which Merz will acquire U.S.-based medical device company Ulthera, a deal which will accelerate Merz’s growth in the aesthetics area and expand the company’s portfolio of treatment options in facial aesthetics.

  • 23. May 2014

    Beat Neukom Is the New CFO of Merz Group

    The Merz Group is expanding its management team to include yet another executive with an international background. As of July 1, 2014, Beat Neukom will be the Merz Group’s Chief Financial Officer, and therefore a member of the Merz Pharma Board.

  • 10. April 2014

    Belotero – An innovative hyaluronic acid dermal filler range by Merz Aesthetics

    Frankfurt, April 10, 2014 – Merz Aesthetics, a division of Merz Pharmaceuticals and global leader in the field of aesthetics, proudly introduces Belotero®: its range of innovative hyaluronic acid fillers, provided with and without lidocaine.

  • 15. November 2013

    The Merz Pharma Group successful after realignment

    Growth continues / Group revenue increases by 7.4 % to EUR 980.2 million / vigorous growth in foreign operations and the aesthetics business / portfolio broadened by successful acquisitions / positive trends validate corporate strategy

  • 08. November 2013

    Merz Pharma acquires Swiss aesthetic medicine specialist Anteis

    Merz Pharma today announced that it has purchased the Swiss company Anteis S.A., which is specialized in the development, manufacture and commercialization of biomedical products in the area of aesthetics. This completes a union of two companies that have been working in strong and trustworthy partnership for many years. The acquisition strengthens Merz Aesthetics’ portfolio and reinforces its market position in the field of aesthetic medicine while merging Anteis’ operations into one of the leading providers worldwide.

  • 22. October 2013

    She makes cell structures light up: Merz’ visiting professor Jennifer Lippincott-Schwartz gives an insight into the undiscovered inner of cells

    Prof. Jennifer Lippincott-Schwartz was assigned to the Friedrich Merz Foundation’s Visiting Professorship, which offers topics ranging from basic research to health care research.

Login for Professionals

last update 06. Mai 2015, 11:10 Uhr

produced by GPM mbH

Extended search

Filter results on the following areas

Merz [Logo] Merz [Logo]

Welcome to Merz - Merz Pharma

Stand: 24-May-2015, 11:00 AM
© 2015 Merz Pharma. All rights reserved.